Drug companies rapped for anticompetitive behaviour


The Italian health ministry is following up on rulings from the country’s competition authorities and demanding billions of euros in damages resulting from anticompetitive behaviour.

The charges relate to Roche and Novartis’s alleged restriction of competition between two related antibody drugs that the two firms co-promote. Lucentis (ranibizumab) and Avastin (bevacizumab) are derived from the same monoclonal antibody that inhibits blood vessel growth.

Avastin is approved for treating certain cancers, whereas Lucentis is used to treat vision loss caused by age-related wet macular degeneration (AMD). But since Avastin is much cheaper, doctors have tended to try and use it off-label to treat AMD. The Italian authorities claim the companies made an agreement to block sales of Avastin in favour of Lucentis, and have asked for €1.2 billion (£977 million) in damages covering 2012–2014. The companies have denied any wrongdoing.

In the same action, the ministry is seeking damages from Pfizer for allegedly abusing its market monopoly position regarding the eye drug Xatalan (latanoprost), by preventing eligible generic versions from entering the market.


Related Content

Roche rapped for side-effect reporting failure

26 June 2012 Business

news image

European medicines regulator names and shames Swiss giant for not disclosing 80,000 instances of potential adverse drug react...

Weathering the storm

6 January 2014 Business

news image

Pharmaceutical industry roundup 2013

Most Read

Coated nanoparticles show Alzheimer's promise

12 September 2014 News and Analysis

news image

Gold nanoparticles functionalised with amino acid polymer inhibit the growth of amyloid fibres associated with neurodegenerat...

First flexible graphene display paves the way for folding electronics

11 September 2014 News and Analysis

news image

Team behind the bendy e-reader display hope to have a full colour graphene-based smartphone style screen within a year

Most Commented

US genomics lead being lost to China

17 September 2014 News and Analysis

news image

NIH senior leaders are sounding the alarm bells, saying the US's pre-eminence in genomics research is under threat

The trouble with boycotts

29 August 2014 Critical Point

news image

Cutting academic ties with a censured state can do more harm than good, says Mark Peplow